Urologic Oncology: Seminars and Original Investigations
Volume 27, Issue 6 , Pages 585-591 , November 2009

Friend or foe? Role of peroxisome proliferator-activated receptor-γ in human bladder cancer

  • Teruo Inamoto, M.D.

      Affiliations

    • Department of Urology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
    • ,
  • Jay B. Shah, M.D.

      Affiliations

    • Department of Urology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
    • ,
  • Ashish M. Kamat, M.D.

      Affiliations

    • Department of Urology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
    • Department of Cancer Biology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-713-792-3250; fax: +1-713-794-4824

Received 14 August 2008 ,Revised 4 November 2008 ,Accepted 9 November 2008.

References 

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA: Cancer J Clin. 2007;57:43–66
  2. Dreicer R, Manola J, Roth BJ, et al. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. Cancer. 2004;100:1639–1645
  3. Sternberg CN, de Mulder P, Schornagel JH, et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer. 2006;42:50–54
  4. Eibl G, Reber HA, Hines OJ, et al. COX and PPAR: Possible interactions in pancreatic cancer. Pancreas. 2004;29:247–253
  5. Gustafsson A, Hansson E, Kressner U, et al. EP1-4 subtype, COX, and PPAR γ receptor expression in colorectal cancer in prediction of disease-specific mortality. Int Journal Cancer. 2007;121:232–240
  6. Johnstone CN, Mongroo PS, Rich AS, et al. Parvin-beta inhibits breast cancer tumorigenicity and promotes CDK9-mediated peroxisome proliferator-activated receptor γ 1 phosphorylation. Mol Cell Biol. 2008;28:687–704
  7. Koh WP, Yuan JM, Van Den Berg D, et al. Peroxisome proliferator-activated receptor (PPAR) γ gene polymorphisms and colorectal cancer risk among Chinese in Singapore. Carcinogenesis. 2006;27:1797–1802
  8. Morita D, Ichikura T, Mochizuki H. The expression of PPAR γ in gastric cancer. Nippon Rinsho. 2001;59(Suppl 4):595–597
  9. Nagamine M, Okumura T, Tanno S, et al. PPAR γ ligand-induced apoptosis through a p53-dependent mechanism in human gastric cancer cells. Cancer science. 2003;94:338–343
  10. Radhakrishnan SK, Gartel AL. The PPAR-γ agonist pioglitazone post-transcriptionally induces p21 in PC3 prostate cancer but not in other cell lines. Cell cycle (Georgetown). 2005;4:582–584
  11. Wang X, Southard RC, Allred CD, et al. MAZ drives tumor-specific expression of PPAR γ 1 in breast cancer cells. Breast Cancer Res Treat. 2008;111:103–111
  12. Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors (PPARs): Nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res. 2000;49:497–505
  13. Jump DB, Clarke SD, Thelen A, et al. Dietary fat, genes, and human health. Advances in experimental medicine and biology. 1997;422:167–176
  14. Telliez A, Furman C, Pommery N, et al. Mechanisms leading to COX-2 expression and COX-2 induced tumorigenesis: Topical therapeutic strategies targeting COX-2 expression and activity. Anticancer Agents Med Chem. 2006;6:187–208
  15. Grommes C, Landreth GE, Heneka MT. Antineoplastic effects of peroxisome proliferator-activated receptor γ agonists. Lancet Oncol. 2004;5:419–429
  16. Nahle Z. PPAR trilogy from metabolism to cancer. Curr Opin Clin Nutr Metabolic Care. 2004;7:397–402
  17. Panigrahy D, Huang S, Kieran MW, et al. PPARγ as a therapeutic target for tumor angiogenesis and metastasis. Cancer Biol Ther. 2005;4:687–693
  18. Peraza MA, Burdick AD, Marin HE, et al. The toxicology of ligands for peroxisome proliferator-activated receptors (PPAR). Toxicol Sci. 2006;90:269–295
  19. Rumi MA, Ishihara S, Kazumori H, et al. Can PPARγ ligands be used in cancer therapy?. Cur Med Chem. 2004;4:465–477
  20. Corton JC, Anderson SP, Stauber A. Central role of peroxisome proliferator-activated receptors in the actions of peroxisome proliferators. Annu Rev Pharmacol Toxicol. 2000;40:491–518
  21. Brun RP, Tontonoz P, Forman BM, et al. Differential activation of adipogenesis by multiple PPAR isoforms. Genes Dev. 1996;10:974–984
  22. Murad H, Collet P, Huin-Schohn C, et al. Effects of PPAR and RXR ligands in semaphorin 6B gene expression of human MCF-7 breast cancer cells. Int J Oncol. 2006;28:977–984
  23. Altiok S, Xu M, Spiegelman BM. PPARγ induces cell cycle withdrawal: Inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A. Genes Dev. 1997;11:1987–1998
  24. Budman DR, Calabro A. Studies of synergistic and antagonistic combinations of conventional cytotoxic agents with the multiple eicosanoid pathway modulator LY 293111. Anticancer Drugs. 2004;15:877–881
  25. Qin C, Morrow D, Stewart J, et al. A new class of peroxisome proliferator-activated receptor γ (PPARγ) agonists that inhibit growth of breast cancer cells: 1,1-Bis(3′-indolyl)-1-(p-substituted phenyl)methanes. Mol Cancer Ther. 2004;3:247–260
  26. Sato H, Ishihara S, Kawashima K, et al. Expression of peroxisome proliferator-activated receptor (PPAR)γ in gastric cancer and inhibitory effects of PPARγ agonists. Br J Cancer. 2000;83:1394–1400
  27. Yoshimura R, Matsuyama M, Segawa Y, et al. Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. Int J Cancer. 2003;104:597–602
  28. Segawa Y, Yoshimura R, Hase T, et al. Expression of peroxisome proliferator-activated receptor (PPAR) in human prostate cancer. The Prostate. 2002;51:108–116
  29. Varley CL, Garthwaite MA, Cross W, et al. PPARγ-regulated tight junction development during human urothelial cytodifferentiation. J Cell Physiol. 2006;208:407–417
  30. Possati L, Rocchetti R, Talevi S, et al. The role of peroxisome proliferator-activated receptor γ in bladder cancer in relation to angiogenesis and progression. Gen Pharmacol. 2000;35:269–275
  31. Nakashiro KI, Hayashi Y, Kita A, et al. Role of peroxisome proliferator-activated receptor γ and its ligands in non-neoplastic and neoplastic human urothelial cells. Am J Pathol. 2001;159:591–597
  32. Guan YF, Zhang YH, Breyer RM, et al. Expression of peroxisome proliferator-activated receptor γ (PPARγ) in human transitional bladder cancer and its role in inducing cell death. Neoplasia (New York). 1999;1:330–339
  33. Kroll TG, Sarraf P, Pecciarini L, et al. PAX8-PPARγ1 fusion oncogene in human thyroid carcinoma [corrected]. Science (New York). 2000;289:1357–1360
  34. Sarraf P, Mueller E, Smith WM, et al. Loss-of-function mutations in PPAR γ associated with human colon cancer. Mol Cell. 1999;3:799–804
  35. Badawi AF, Eldeen MB, Liu Y, et al. Inhibition of rat mammary gland carcinogenesis by simultaneous targeting of cyclooxygenase-2 and peroxisome proliferator-activated receptor γ. Cancer Res. 2004;64:1181–1189
  36. Suh N, Wang Y, Williams CR, et al. A new ligand for the peroxisome proliferator-activated receptor-γ (PPAR-γ), GW7845, inhibits rat mammary carcinogenesis. Cancer Res. 1999;59:5671–5673
  37. Tanaka T, Kohno H, Yoshitani S, et al. Ligands for peroxisome proliferator-activated receptors alpha and γ inhibit chemically induced colitis and formation of aberrant crypt foci in rats. Cancer Res. 2001;61:2424–2428
  38. Kohno H, Yoshitani S, Takashima S, et al. Troglitazone, a ligand for peroxisome proliferator-activated receptor γ, inhibits chemically-induced aberrant crypt foci in rats. Jpn J Cancer Res. 2001;92:396–403
  39. Lefebvre AM, Chen I, Desreumaux P, et al. Activation of the peroxisome proliferator-activated receptor γ promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat Med. 1998;4:1053–1057
  40. Saez E, Tontonoz P, Nelson MC, et al. Activators of the nuclear receptor PPARγ enhance colon polyp formation. Nat Medicine. 1998;4:1058–1061
  41. Cui Y, Miyoshi K, Claudio E, et al. Loss of the peroxisome proliferation-activated receptor γ (PPARγ) does not affect mammary development and propensity for tumor formation but leads to reduced fertility. J Biol Chem. 2002;277:17830–17835
  42. Takeda K, Ichiki T, Tokunou T, et al. 15-Deoxy-δ12,14-prostaglandin J2 and thiazolidinediones activate the MEK/ERK pathway through phosphatidylinositol 3-kinase in vascular smooth muscle cells. J Biol Chem. 2001;276:48950–48955
  43. Haraguchi K, Shimura H, Onaya T. Activation of peroxisome proliferator-activated receptor-107 inhibits apoptosis induced by serum deprivation in LLC-PK1 cells. Exp Nephrol. 2002;10:393–401
  44. Wang YL, Frauwirth KA, Rangwala SM, et al. Thiazolidinedione activation of peroxisome proliferator-activated receptor γ can enhance mitochondrial potential and promote cell survival. J Biol Chemistry. 2002;277:31781–31788
  45. Leibovici D, Grossman HB, Dinney CP, et al. Polymorphisms in inflammation genes and bladder cancer: From initiation to recurrence, progression, and survival. J Clin Oncol. 2005;23:5746–5756
  46. Kassouf W, Chintharlapalli S, Abdelrahim M, et al. Inhibition of bladder tumor growth by 1,1-bis(3>29>-indolyl)-1-(p-substituted phenyl) methanes: A new class of peroxisome proliferator-activated receptor γ agonists. Cancer Res. 2006;66:412–418
  47. Fauconnet S, Lascombe I, Chabannes E, et al. Differential regulation of vascular endothelial growth factor expression by peroxisome proliferator-activated receptors in bladder cancer cells. J Biol Chem. 2002;277:23534–23543
  48. Ikeda E, Achen MG, Breier G, et al. Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J Biol Chem. 1995;270:19761–19766
  49. Crew JP, O'Brien T, Bradburn M, et al. Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res. 1997;57:5281–5285
  50. Zlotta AR, van Vooren JP, Huygen K, et al. What is the optimal regimen for BCG intravesical therapy? (Are six weekly instillations necessary?). Eur Urol. 2000;37:470–477
  51. Kamat AM, Dinney CP. A combination of intravesical BCG [corrected] and [corrected] electromotive mitomycin for high-risk superficial bladder cancer. Nat Clin Pract. 2006;3:472–473
  52. Smith JA, Labasky RF, Cockett AT, et al. Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1, and TIS). Am Urol Assoc, J Urol. 1999;162:1697–1701
  53. Oosterlinck W, Lobel B, Jakse G, et al. Guidelines on bladder cancer. Eur Urol. 2002;41:105–112
  54. Sylvester RJ, van der MA, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: A meta-analysis of the published results of randomized clinical trials. J Urol. 2002;168:1964–1970
  55. Lodillinsky C, Umerez MS, Jasnis MA, et al. Bacillus Calmette-Guerin induces the expression of peroxisome proliferator-activated receptor γ in bladder cancer cells. Int J Mol Med. 2006;17:269–273
  56. Kukreja A, Costi G, Marker J, et al. NKT cell defects in NOD mice suggest therapeutic opportunities. J Autoimmune. 2002;19:117–128
  57. Maclaren N, Lan M, Coutant R, et al. Only multiple autoantibodies to islet cells (ICA), insulin, GAD65, IA-2, and IA-2β predict immune-mediated (type 1) diabetes in relatives. J Autoimmune. 1999;12:279–287
  58. DuBois RN, Gupta R, Brockman J, et al. The nuclear eicosanoid receptor, PPARγ, is aberrantly expressed in colonic cancers. Carcinogenesis. 1998;19:49–53
  59. Gupta RA, Brockman JA, Sarraf P, et al. Target genes of peroxisome proliferator-activated receptor γ in colorectal cancer cells. J Biol Chem. 2001;276:29681–29687
  60. Lehmann JM, Moore LB, Smith-Oliver TA, et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J Biol Chem. 1995;270:12953–12956
  61. Panigrahy D, Shen LQ, Kieran MW, et al. Therapeutic potential of thiazolidinediones as anticancer agents. Expert Opin Investig Drugs. 2003;12:1925–1937
  62. Koeffler HP, Sparkes RS, Billing R, et al. Somatic cell hybrid analyses of hematopoietic differentiation. Blood. 1981;58:1159–1163
  63. Michalik L, Desvergne B, Wahli W. Peroxisome-proliferator-activated receptors and cancers: Complex stories. Nat Rev. 2004;4:61–70
  64. Theocharisa S, Margeli A, Kouraklis G. Peroxisome proliferator activated receptor-γ ligands as potent antineoplastic agents. Curr Med Chem. 2003;3:239–251
  65. Tontonoz P, Singer S, Forman BM, et al. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor γ and the retinoid X receptor. Proc Natl Acad Sci USA. 1997;94:237–241
  66. Brockman JA, Gupta RA, Dubois RN. Activation of PPARγ leads to inhibition of anchorage-independent growth of human colorectal cancer cells. Gastroenterology. 1998;115:1049–1055
  67. Elstner E, Muller C, Koshizuka K, et al. Ligands for peroxisome proliferator-activated receptor γ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA. 1998;95:8806–8811
  68. Kubota T, Koshizuka K, Williamson EA, et al. Ligand for peroxisome proliferator-activated receptor γ (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res. 1998;58:3344–3352
  69. Sarraf P, Mueller E, Jones D, et al. Differentiation and reversal of malignant changes in colon cancer through PPARγ. Nat Med. 1998;4:1046–1052
  70. Gardner OS, Dewar BJ, Graves LM. Activation of mitogen-activated protein kinases by peroxisome proliferator-activated receptor ligands: An example of nongenomic signaling. Mol Pharmacol. 2005;68:933–941
  71. Jain A, Agus DB. PPARγ signaling: One size fits all?. Cell Cycle (Georgetown). 2004;3:1352–1354
  72. Rubenstrunk A, Hanf R, Hum DW, et al. Safety issues and prospects for future generations of PPAR modulators. Biochim Biophys Acta. 2007;1771:1065–1081

PII: S1078-1439(08)00327-X

doi: 10.1016/j.urolonc.2008.11.002

Urologic Oncology: Seminars and Original Investigations
Volume 27, Issue 6 , Pages 585-591 , November 2009

Article Tools